Peptide Stacks · Exact presentation
CJC-1295 DAC + Ipamorelin · 5 mg + 5 mg Stack
CJC-1295 DAC + Ipamorelin · 5 mg + 5 mg Stack describes separate products coordinated in one research reference. It does not represent a single-vial blend.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Dosing & Reconstitution Guide
No reconstitution extrapolation is published because the unit, formulation, or composition does not support one reliable calculation from the source inventory. Reference concentration stated by the source: 2.5 mg/mL. It must be checked against the actual formulation and documentation.
CJC-1295 DAC (5 mg Vial) — Subcutaneous, Once Weekly
CJC-1295 DAC + Ipamorelin · 5 mg + 5 mg Stack describes separate products coordinated in one research reference. It does not represent a single-vial blend.
CJC-1295 DAC (5 mg Vial) — Subcutaneous, Once Weekly
| Phase | Weekly Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Standard | 1000 mcg (1.0 mg) | 40 units (0.40 mL) | Once weekly |
| Aggressive | 2000 mcg (2.0 mg) | 80 units (0.80 mL) | Once weekly |
CJC-1295 DAC Reconstitution Steps
No reconstitution extrapolation is published because the unit, formulation, or composition does not support one reliable calculation from the source inventory. Reference concentration stated by the source: 2.5 mg/mL. It must be checked against the actual formulation and documentation.
Ipamorelin (5 mg Vial) — Subcutaneous, Once Daily
CJC-1295 DAC + Ipamorelin · 5 mg + 5 mg Stack describes separate products coordinated in one research reference. It does not represent a single-vial blend.
Ipamorelin (5 mg Vial) — Subcutaneous, Once Daily
| Phase | Daily Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Weeks 1–2 (Initiation) | 100 mcg (0.1 mg) | 6 units (0.06 mL) | Once daily |
| Weeks 3–4 (Titration) | 150 mcg (0.15 mg) | 9 units (0.09 mL) | Once daily |
| Weeks 5+ (Maintenance) | 200 mcg (0.2 mg) | 12 units (0.12 mL) | Once daily |
| Aggressive (Optional) | 300 mcg (0.3 mg) | 18 units (0.18 mL) | Once daily or split 2×/day |
Ipamorelin Reconstitution Steps
No reconstitution extrapolation is published because the unit, formulation, or composition does not support one reliable calculation from the source inventory. Reference concentration stated by the source: 2.5 mg/mL. It must be checked against the actual formulation and documentation.
Combined Stack Schedule — Standard Approach
The source chart summarizes “1 mg–2 mg” at “Weekly” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Combined Stack Schedule — Standard Approach
| Week | CJC-1295 DAC (Weekly) | Ipamorelin (Daily) |
|---|---|---|
| Weeks 1–2 | 1000 mcg (40 units) once weekly | 100 mcg (6 units) once daily |
| Weeks 3–4 | 1000 mcg (40 units) once weekly | 150 mcg (9 units) once daily |
| Weeks 5–12 | 1000 mcg (40 units) once weekly | 200 mcg (12 units) once daily |
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
The proposed mechanism depends on the molecular identity and receptor systems described in the literature. A mechanism alone does not establish clinical efficacy.
Potential Benefits & Side Effects
Identity, purity, sterility, stability, and equivalence to studied products cannot be assumed. Adverse effects and interactions may be incompletely characterized.
Source trail
Scientific references and source discovery
- PeptideDosages — exact CJC-1295 DAC + Ipamorelin · 5 mg + 5 mg Stack entrysecondary-structure
- PubMed — literature search for CJC-1295 DAC + Ipamorelinprimary-discovery
- ClinicalTrials.gov — study search for CJC-1295 DAC + Ipamorelintrial-registry
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference